BCAB on OTC
BioAtla
Company in San Diego, United States.1
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Applied Genetic Technologies Corporation, Inhibikase Therapeutics, Inc. or Artiva Biotherapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2021
Where the money goes
Where each dollar of revenue went, fiscal 2021
- Research and development100¢$58.3M
- Interest0¢$3.0K
Out of $300.0K in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration and other revenue | $2.0M | $11.0M |
| Research and development expense | $43.6M | $63.1M |
| General and administrative expense | $17.7M | $21.8M |
| Total operating expenses | $61.3M | $84.9M |
| Loss from operations | -$59.3M | -$73.9M |
| Interest income | $843.0K | $3.4M |
| Gain on warrant liability | $295.0K | $807.0K |
| Loss on PPAs liability | -$406.0K | $0 |
| Other expense | -$1.0M | -$9.0K |
| Total other income (expense) | -$302.0K | $4.2M |
| Consolidated net loss and comprehensive loss | -$59.6M | -$69.8M |
| Net loss per common share, basic | -$1.01 | -$1.44 |
| Net loss per common share, diluted | -$1.01 | -$1.44 |
| Weighted-average shares of common stock outstanding, basic | 58.8M shares | 48.6M shares |
| Weighted-average shares of common stock outstanding, diluted | 58.8M shares | 48.6M shares |
| Related party amounts | $300.0K | $2.1M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $7.1M | $49.0M | |
| Prepaid expenses and other current assets | $895.0K | $2.2M | |
| Total current assets | $8.0M | $51.2M | |
| Property and equipment, net | $120.0K | $678.0K | |
| Operating lease right-of-use-asset, net | $5.5M | $6.0M | $512.0K |
| Other assets | $163.0K | $0 | |
| Total assets | $13.8M | $52.4M | |
| Accounts payable and accrued expenses | $16.4M | $13.7M | |
| Operating lease liabilities | $1.4M | $836.0K | |
| PPAs liability | $4.1M | $0 | |
| Total current liabilities | $21.9M | $14.5M | |
| Operating lease liabilities, less current portion | $4.8M | $0 | |
| Liability to licensor | $19.8M | $19.8M | |
| Warrant liability | $3.5M | $3.8M | |
| Total liabilities | $50.0M | $38.2M | |
| Preferred stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock value | $6.0K | $6.0K | |
| Additional paid-in capital | $509.5M | $500.3M | |
| Accumulated deficit | -$545.6M | -$486.0M | |
| Total stockholders' equity (deficit) | -$36.2M | $14.3M | |
| Total liabilities and stockholders' equity (deficit) | $13.8M | $52.4M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | |
| Common stock, shares issued (in shares) | 63.5M shares | 58.1M shares | |
| Common stock, shares outstanding (in shares) | 63.5M shares | 58.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$59.6M | -$69.8M |
| Depreciation and amortization | $373.0K | $925.0K |
| Loss on disposal of property and equipment | $185.0K | $0 |
| Change in fair value of warrant liability | -$295.0K | -$807.0K |
| Change in fair value of PPAs liability | $406.0K | $0 |
| Commitment fee under SEPA | $282.0K | $0 |
| Financing costs related to PPAs | $742.0K | $0 |
| Stock-based compensation | $5.4M | $8.9M |
| Prepaid expenses and other assets | $1.1M | $2.9M |
| Accounts payable and accrued expenses | $2.8M | -$13.5M |
| Right-of-use assets and lease liabilities, net | $344.0K | -$641.0K |
| Net cash used in operating activities | -$48.2M | -$71.9M |
| Proceeds from PPAs | $7.1M | $0 |
| Payment of financing costs related to issuance of common stock, PPAs and SEPA | -$897.0K | $0 |
| Proceeds from issuance of common stock and warrants, net of issuance costs | $0 | $9.2M |
| Proceeds from issuance of common stock under Employee Stock Purchase Plan | $100.0K | $342.0K |
| Payments for taxes related to net settlement of equity awards | -$52.0K | -$46.0K |
| Net cash provided by financing activities | $6.3M | $9.5M |
| Net decrease in cash and cash equivalents | -$41.9M | -$62.4M |
| Increase in right-of-use assets and operating lease liabilities resulting from contract modification | $6.0M | $0 |
| PPAs related costs included in accounts payable and accrued expense | $289.0K | $0 |
| Fair value of common stock issued in satisfaction of PPAs liability | $3.4M | $0 |
| Equity issuance costs included in accounts payable and accrued expense | $0 | $445.0K |
Leadership
Who has led BioAtla, and when. Pick a name to see everywhere that person has worked.
2010201520202025
- FounderJay Short1
- ChairScott A. Smith Sep 2018 to Feb 20231
Timeline
- 2007Founded Founded1
Recent filings
- Sep 29, 20268-K
- Sep 2, 20264
- Sep 2, 20264
- Sep 2, 20264
- Aug 28, 20268-K
- Aug 13, 202610-Q
- Jul 16, 20268-K
- Jun 5, 20264
- Jun 5, 20264
- Jun 5, 20264
- Jun 3, 2026DEF 14A
- Jun 3, 2026DEFA14A
- Jun 3, 2026ARS
- May 15, 202610-Q
- Apr 29, 202610-K/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- WikidataQ104480051
- SEC EDGARCIK 1826892
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataBioAtla on Wikidata
- 2SEC EDGARBioAtla filings on SEC EDGAR
- 3SEC EDGARBioAtla 10-K for fiscal 2025
- 4SEC EDGARBioAtla filings on SEC EDGAR
- 5SEC EDGARBioAtla 10-K for fiscal 2021
- 6SEC EDGARBioAtla 10-K for fiscal 2019
- 7SEC EDGARBioAtla 10-Q for fiscal 2025
- 8SEC EDGARBioAtla 10-Q for fiscal 2025
- 9SEC EDGARBioAtla 10-Q for fiscal 2026
- 10SEC EDGARBioAtla 10-Q for fiscal 2025